GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03462810|
Expanded Access Status : Available
First Posted : March 13, 2018
Last Update Posted : May 21, 2021
- Study Details
- Tabular View
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Infection, Human Immunodeficiency Virus||Drug: cabotegravir, CAB|
|Study Type :||Expanded Access|
|Expanded Access Type :||Individual Patients|
|See clinical trials of the intervention/treatment in this expanded access record.|
|Official Title:||GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV|
- Drug: cabotegravir, CAB
open label investigational productOther Names:
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
HIV-infected patients will be eligible for treatment if ALL the following apply:
- Male or female patients aged ≥ 18 yrs
NOTE: all female patients of reproductive potential should use every precaution to prevent pregnancy including either complete abstinence from intercourse from 2 weeks prior to administration of CAB, throughout receipt of CAB and for at least 52 weeks after discontinuation of CAB LA; or use of one of the following methods of highly reliable contraception:
- Contraceptive subdermal implant
- Intrauterine device or intrauterine system
- Combined estrogen and progestogen oral contraceptive
- Injectable progestogen
- Contraceptive vaginal ring
- Percutaneous contraceptive patches
- Male partner sterilisation with documentation of azoospermia prior to the female subject's entry into the study, and this male is the sole partner for that subject. The documentation on male sterility can come from the site personnel's: review of subject's medical records, medical examination and/or semen analysis, or medical history interview provided by her or her partner.
These allowed methods of contraception are only effective when used consistently/correctly and in accordance with the product label. The investigator is responsible for ensuring that patients understand how to properly use these methods of contraception.
- Inability to construct a viable antiviral treatment regimen with commercially available medications;
- Demonstrated need for a long acting, injectable antiretroviral including, but not limited to malabsorption or inability to achieve adequate drug levels via oral route. NOTE: Poor/incomplete adherence to oral meds is not a sufficient rationale for inclusion.
- The patient/legal guardian or representative has given informed consent to treatment prior to administering CAB (in a manner consistent with all national requirements). The patient/legal guardian or representative has also given informed consent for the transmission of a copy of the anonymized adverse and serious adverse event (SAE) and pregnancy reports (in compliance with local regulatory authority requirements) to GSK and ViiV where allowable by local regulations, and to the country regulatory authority as required.
Patients will not be eligible for treatment if ANY of the following apply:
- Patient has estimated creatinine clearance <50 mL/min via Cockcroft-Gault method;
- Females who are pregnant or women who are breastfeeding, or plan to become pregnant or breastfeed during treatment.
- Patients who have had known or suspected allergic reaction or hypersensitivity reactions to integrase inhibitors;
- Alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN)
- ALT ≥ 3 times ULN and bilirubin ≥ 1.5 times ULN (with > 35% direct bilirubin)
- Evidence for moderate to severe hepatic impairment, grade 3-4 liver fibrosis, or cirrhosis
- Patients who are eligible for actively enrolling clinical trials involving CAB.
- Significant coagulopathy precluding chronic IM dosing
NOTE: Patients should not be treated via the named patient/compassionate use program if they are eligible and/or able to participate in any of the Phase III clinical trials of CAB and the patient is suitable for participation in such clinical trials. In that instance (assuming consent is obtained) the patient should preferentially be enrolled into the ongoing clinical trial to allow detailed data collection. In accordance with national requirements patients should not be treated in the named patient/compassionate use program if they have responded to previous treatment with CAB in another clinical trial without review and prior approval by the VSLC.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03462810
|Contact: US GSK Clinical Trials Call Center||877-379-3718||GSKClinicalSupportHD@gsk.com|
|Study Director:||GSK Clinical Trials||ViiV Healthcare|
|Responsible Party:||ViiV Healthcare|
|Other Study ID Numbers:||
|First Posted:||March 13, 2018 Key Record Dates|
|Last Update Posted:||May 21, 2021|
|Last Verified:||October 2020|
Individual Patient Compassionate Use
Acquired Immunodeficiency Syndrome
Immunologic Deficiency Syndromes
Immune System Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
RNA Virus Infections
Slow Virus Diseases
HIV Integrase Inhibitors
Molecular Mechanisms of Pharmacological Action